Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions
Robert I. Haddad(Georgetown University), Jan B. Vermorken(University of Antwerp), Ricardo Hitt(Hospital Universitario Severo Ochoa), Ezra E.W. Cohen(Moores Cancer Center), J. Schulten(Merck (Germany)), M. Posner(Icahn School of Medicine at Mount Sinai), J.-L. Lefebvre(Centre Oscar Lambret)
Cited by 150
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
|New England Journal of Medicine|2008|3.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k